STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

EP Europace Journal

6 March 2023
Organised by: Logo
ESC Journals ARRHYTHMIAS AND DEVICE THERAPY Device Therapy

Abstract

Abstract

The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions’ experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.

Contributors

Melanie Grehn
Melanie Grehn

Author

University Medical Center of Schleswig-Holstein Kiel , Germany

Etienne Pruvot
Etienne Pruvot

Author

University Hospital Centre Vaudois (CHUV) Lausanne , Switzerland

Matteo Anselmino
Matteo Anselmino

Author

Hospital Citta Della Salute e della Scienza di Torino Turin , Italy

Otakar Jiravsky
Otakar Jiravsky

Author

Hospital Podlesi Trinec , Czechia

Mario Levis
Mario Levis

Author

University of Turin Turin , Italy

Julio Martí-Almor
Julio Martí-Almor

Author

Teknon Medical Centre Barcelona , Spain

Giulio Molon
Giulio Molon

Author

IRCCS Sacro Cuore - Don Calabria Negrar , Italy

Petr Peichl
Petr Peichl

Author

Institute for Clinical and Experimental Medicine (IKEM) Prague , Czechia

Pieter G Postema
Pieter G Postema

Author

Amsterdam University Medical Centre (AUMC) Amsterdam , Netherlands (The)

Aurelio Quesada
Aurelio Quesada

Author

University General Hospital of Valencia Valencia , Spain

Roberto Rordorf
Roberto Rordorf

Author

Foundation IRCCS Policlinic San Matteo - University of Pavia Pavia , Italy

Boris Rudic
Boris Rudic

Author

Hospital Frankfurt Hochst Frankfurt am Main , Germany

Rachel M A ter Bekke
Rachel M A ter Bekke

Author

Cardiovascular Research Institute Maastricht (CARIM) Maastricht , Netherlands (The)